Overview

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
0
Participant gender:
All
Summary
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:

- Wet AMD, Visual Acuity from 20/320 to 20/40

Exclusion Criteria:

- Diabetic retinopathy, laser coagulation history